Oligonucleotide API Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Global Oligonucleotide API Market Trends and Insights

Advancing Oligonucleotide Therapeutic Pipelines

The oligonucleotide API market draws much of its near-term demand from the progression of clinical programs into later development stages. A broader set of RNA therapeutic candidates requires clinical-grade material before commercial manufacturing begins. Early-stage programs can also establish supplier relationships well before pivotal trials, which gives capable manufacturers a longer view of future demand. The 2025 approvals of fitusiran, donidalorsen, and plozasiran, following olezarsen in 2024, showed that multiple oligonucleotide approaches can reach commercial use. The approved therapies cover different treatment settings and support demand across antisense and siRNA supply chains. This progression encourages developers to secure manufacturing expertise before the timeline for large-scale supply becomes tight.

Expansion of GMP Oligonucleotide CDMO Capacity

GMP capacity is expanding as sponsors seek dependable supply for development and marketed programs in the oligonucleotide API market. Bachem inaugurated Building K in Switzerland in April 2026 after investing CHF 332.6 million (USD 407.6 million) in 2025 and planning CHF 350 million (USD 428.9 million) to CHF 400 million (USD 490.2 million) of further investment for 2026. BioSpring is building a GMP facility in Germany that covers more than 15,200 m² and is scheduled for completion in 2027^[1]. Nippon Shokubai announced a tenfold expansion of GMP-compliant nucleic acid drug API capacity in June 2025, with operations targeted for 2027. These programs broaden the number of qualified facilities that can support complex development and commercial work. They also make location, technology breadth, and regulatory experience more important in supplier selection.

Increasing Adoption of Precision Medicine and RNA-Based Therapies

The oligonucleotide API market benefits as RNA-based medicines address well-defined genetic and molecular targets. GalNAc-linked siRNA medicines have shown that infrequent subcutaneous dosing can support treatment beyond the earliest intravenous lipid nanoparticle products. This delivery profile makes RNA approaches more relevant for chronic conditions and dispersed patient populations. The approvals of fitusiran and plozasiran in 2025 reflected this wider use of targeted RNA modalities. Developers must still demonstrate sequence identity, impurity control, and consistent product quality as programs move through development. Those requirements favor suppliers with established process development, analytical, and GMP capabilities.

Rising Demand for Complex Conjugated Oligonucleotide APIs

Conjugated medicines are changing the technical requirements of the oligonucleotide API market. GalNAc remains important for liver targeting, while other targeting approaches include integrin-binding peptides, antibody-oligonucleotide conjugates, and extended nucleic acid modifications. These designs require careful control of both the oligonucleotide and the attached ligand or modified backbone. Hongene Biotech licensed technology from UMass Chan Medical School in August 2025 to produce exNA phosphoramidites, showing how new chemistries can increase upstream material needs. The added complexity increases the importance of process development at an early stage. It can also make a manufacturing partner harder to replace once the program reaches clinical supply.

High Purification, Yield, and Impurity-Control Costs

Purification remains a central constraint on the oligonucleotide API market because closely related failure sequences are difficult to remove. Solid-phase synthesis can produce molecules that differ by only 1 nucleotide, so manufacturers may need multiple ion-exchange or reverse-phase chromatography steps. Modified sequences are especially challenging because practical yields can remain below 50%. The process also creates substantial demands for buffers, testing, and documented control of each manufacturing stage. The International Society for Pharmaceutical Engineering noted that these requirements complicate scale-up and increase waste-management demands^[2]. Higher production costs can limit access when developers target larger patient populations and need lower per-dose pricing.

Specialty Phosphoramidite and Modified-Monomer Supply Bottlenecks

The oligonucleotide API market depends on specialized phosphoramidites and modified monomers that have a more concentrated supply base than standard pharmaceutical inputs. Chemistries such as 2'-OMe, 2'-F, and locked nucleic acid require multistep production and specialized handling. A disruption in supply can delay process development, clinical manufacturing, or commercial replenishment. This exposure is most significant when a program depends on a customized sequence or proprietary modification. Manufacturers are therefore seeking greater control of upstream materials and a broader qualified supplier base. The effort to develop exNA phosphoramidites illustrates the upstream work needed to support emerging oligonucleotide designs.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By API Type: ASO Leadership Supports a Faster-Growing siRNA Category

Antisense oligonucleotides accounted for 55.31% of the oligonucleotide API market share by API type in 2025. Their position reflects an established set of products in rare, neuromuscular, metabolic, and cardiovascular conditions. Antisense approaches remain important where intrathecal or intraocular delivery is required and systemic delivery alternatives have limited use. The installed base gives suppliers recurring experience with sequence design, process validation, and regulatory documentation. PMO APIs retain a specialized role in Duchenne muscular dystrophy exon-skipping programs. MicroRNA mimics and aptamer APIs have smaller commercial volumes but retain development potential in oncology and other therapeutic areas.

Small interfering RNA APIs are forecast to grow at 10.65% CAGR from 2026 to 2031 in the oligonucleotide API market. GalNAc conjugation supports durable gene silencing and less frequent subcutaneous dosing. Products such as Amvuttra and Leqvio show how this platform can support chronic treatment settings. These characteristics can increase annual API needs when compared with programs serving limited orphan populations. The category also raises demand for conjugation expertise and methods that preserve purity at larger scale. Suppliers that can handle both the oligonucleotide and the targeting ligand are positioned to support this shift.

By Manufacturing Technology: Solid-Phase Synthesis Remains the Current Base

Solid-phase synthesis held 68.24% of the oligonucleotide API market share by manufacturing technology in 2025. Its lead comes from long-standing process knowledge, installed GMP equipment, and regulatory precedent. The method remains widely used for established products and for many clinical programs. Its practical limits become more visible as commercial output rises because column size, solvent consumption, and waste treatment increase with scale. The International Society for Pharmaceutical Engineering reported that larger solid-phase batches can require extensive solvent handling, which complicates facilities intended for high annual volumes. These limitations are encouraging manufacturers to assess alternative methods without abandoning proven chemistry.

Hybrid chemical-enzymatic synthesis is projected to advance at 13.42% CAGR from 2026 to 2031. The approach combines chemically produced fragments with enzymatic ligation to build longer sequences. It can address the limits of single-column solid-phase production while retaining familiar phosphoramidite inputs. Fragment-based assembly may also produce impurity profiles that are more manageable than conventional shortmer failures. Liquid-phase methods are relevant for shorter modified sequences and can lower solvent use in some applications. Research on chemical ligation and liquid-phase approaches supports continued platform development for larger and more complex oligonucleotides^[3].

By Application: Rare and Genetic Diseases Form the Commercial Base

Rare and genetic diseases accounted for 28.24% of oligonucleotide API revenue by application in 2025. Commercially validated mechanisms in spinal muscular atrophy, transthyretin amyloidosis, and familial hypercholesterolemia underpin this position. These programs have established the role of sequence-defined therapeutics in conditions where a clear molecular target is available. Neurological and neuromuscular disorders are another important group because intrathecal ASOs can address targets beyond the reach of many systemic therapies. The blood-brain barrier continues to shape both delivery choices and manufacturing requirements. The resulting portfolio creates demand for specialized sequence, backbone, and purity capabilities.

Gene editing and gene regulation are forecast to expand at 11.52% CAGR from 2026 to 2031. CRISPR programs increasingly need GMP-grade sgRNA APIs, often with sequences exceeding 100 nucleotides. These lengths make impurity control more difficult with conventional solid-phase methods. Longer products can accumulate shortmer impurities and require more intensive purification. The segment therefore gives greater weight to enzymatic, hybrid, and ligation-based approaches. Oncology and immuno-oncology remain earlier commercial applications, while personalized cancer vaccine components and CAR-T programs support preclinical demand for sgRNA material.

By Status: Marketed APIs Hold the Largest Revenue Position

Marketed APIs represented 58.14% of oligonucleotide API market revenue by development status in 2025. This position reflects the premium GMP requirements of approved products and the high technical burden of commercial supply. Commercial programs need consistent output, extensive documentation, and resilient procurement of specialized raw materials. Clinical-trial APIs form an important secondary source of demand because Phase 3 programs need supply that is close to commercial quality. The approved RNA therapeutics landscape has expanded the number of programs that require those capabilities. The Oligonucleotide API industry therefore depends on both current marketed products and a steady conversion of clinical candidates.

Preclinical and discovery-stage APIs are forecast to grow at 11.42% CAGR from 2026 to 2031. The breadth of activity spans CNS, oncology, and gene-editing programs entering IND-enabling work. These projects often introduce extended sequences, new backbone modifications, and emerging targeting ligands. Their immediate volumes may be smaller than marketed programs, but they shape the process capabilities needed for later stages. Suppliers that work with developers at this stage can gain familiarity with methods and analytical requirements before commercial contracts are awarded. This relationship-based model makes early technical support important even when near-term revenue is limited.

By End User: Pharmaceutical Companies Remain the Largest Buyers

Pharmaceutical companies accounted for 42.84% of oligonucleotide API revenue by end user in 2025. Innovators such as Ionis Pharmaceuticals, Alnylam, and Arrowhead have long-term supplier relationships or internal manufacturing assets that influence commercial supply chains. Their programs require reliable GMP material as they move from clinical work to recurrent commercial production. Biotechnology companies remain an important customer group because their molecule portfolios are often concentrated and their dependence on external manufacturing can be high. Academic and research institutes generally access GMP-grade material through CRDMO catalog services for toxicology and mechanistic work. These early studies can become the starting point for future clinical programs.

CRDMOs are forecast to grow at 10.22% CAGR from 2026 to 2031. The service model is moving beyond straightforward manufacturing as providers add process development and chemistry, manufacturing, and controls support. This lets a provider remain involved from lead selection through development and commercialization. A partner that helps solve sequence, purification, and analytical challenges early can become more difficult to replace. The change also increases competition between pure-play CDMOs and broader development service providers. In the Oligonucleotide API industry, the ability to link early technical work with later GMP production is becoming a meaningful part of commercial positioning.

Geography Analysis

North America held 41.41% of oligonucleotide API revenue in 2025. The region combines FDA regulatory experience, a dense group of RNA-focused innovators, and established GMP facilities in Massachusetts, California, and North Carolina. This combination supports both development supply and commercial manufacturing. Regulatory precedent for oligonucleotide chemistry, manufacturing, and controls documentation is a practical advantage for suppliers serving United States-bound programs. Bachem is expanding its United States capacity through 2030 as part of its broader investment program. The oligonucleotide API market in North America also benefits from proximity between developers, analytical specialists, and manufacturing partners.

Europe is the second-largest regional base, with a technical cluster across Germany, Switzerland, and the United Kingdom. Its position is supported by experienced CDMOs and by being close to European regulatory expertise. BioSpring’s German facility is intended to add substantial manufacturing capability when it is completed in 2027. Germany and Switzerland remain important production centers because of their established technical infrastructure. The United Kingdom is also strengthening strategic biomanufacturing capacity under post-Brexit industrial priorities. These factors make Europe an important alternative supply base for sponsors seeking geographic diversity in the oligonucleotide API market.

Asia-Pacific is projected to be the fastest-growing region at 10.25% CAGR from 2026 to 2031. South Korea has become a significant production hub through ST Pharm’s manufacturing activity, while Nippon Shokubai’s planned tenfold expansion adds future capacity in Japan. Cohance Lifesciences announced an INR 230 million (USD 2.39 million) investment in a cGMP oligonucleotide facility in Hyderabad in August 2025. These investments support a wider regional manufacturing network for the oligonucleotide API market. South America, the Middle East, and Africa remain early-stage regions that rely more heavily on imports. Brazil’s pharmaceutical incentives and healthcare localization efforts in the Gulf Cooperation Council could support longer-term demand.